How many tablets does a box of rasagiline tablets usually contain and what are their specifications?

Rasagiline is a commonly used clinical drug for the treatment of Parkinson's disease. It has been on the market in China and overseas markets for many years. It has relatively fixed specifications and dosage form designs, making it easy for patients to use according to the course of treatment. According to the current actual sales situation in domestic pharmacies and import channels, the common original version of rasagiline tablets in China is small packaging of 1 mg × 14 tablets. Some hospitals also supply long-term packaging of 1 mg × 28 tablets or 30 tablets. In overseas markets, especially in the United States and European markets, common specifications include 0.5 mg × 30 tablets and 1 mg × 30 tablets, which facilitates individualized dosage adjustment according to the condition.

Usually, initial treatment adopts a dosage regimen of 1 mg once a day. Therefore, a box of 14 tablets can be used for about two weeks, while 30 tablets can support a full month of treatment. This specification is designed to meet the needs of chronic treatment of Parkinson's disease, helps patients adhere to long-term medication, and facilitates doctors to regularly evaluate efficacy and side effects.

In terms of packaging, Rasagirando is packaged in blister packs, which facilitates divided administration and storage. Some original drug packages also come with instructions in English or Chinese and English, detailing medication precautions, side effects, interactions and other information. When purchasing medicines, patients should pay attention to checking the integrity of the packaging and the batch number to ensure that they are compliant medicines obtained through formal channels.

It is worth mentioning that in the Chinese mainland market, rasagiline is currently mainly the original drug, and there has not yet been a large-scale domestic generic drug on the market. Therefore, its specifications are basically set by the original drug manufacturer. In the future, if domestic companies successfully imitate the drug and pass the consistency evaluation, products with different tablet sizes, dosage forms and more cost-effective products may appear on the market.

Reference materials:https://www.azilect.com/